Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
The SAPPHO Study
NCT06439693Phase 2Recruiting
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Aug 2024
- Primary completion
- Mar 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of trastuzumab, pertuzumab, Paclitaxel Micelles for Injection, docetaxel, paclitaxel in HER2-positive breast cancer, sponsored by Dana-Farber Cancer Institute. Started Aug 2024; status: recruiting.
02
Drugs
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT06439693.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06439693.